Boston Scientific Corporation (BSX)
Why Boston Scientific (BSX) Outpaced the Stock Market Today
Boston Scientific (BSX) reached $42.73 at the closing of the latest trading day, reflecting a +1.64% change compared to its last close.
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Boston Scientific (BSX) concluded the recent trading session at $42.04, signifying a +1.11% move from its prior day's close.
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Boston Scientific (BSX). This makes it worthwhile to examine what the stock has in store.
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Boston Scientific (BSX) closed at $42.6, marking a -1.46% move from the previous day.
Boston Scientific: Market Pessimism Has Pushed The Stock Into Undervalued Territory
Boston Scientific stock slumped 55% over 12 months, driven by weakness in electrophysiology and WATCHMAN, which comprise only 26% of 2025 sales. Despite headline challenges, 74% of BSX's business grew at a robust 7% in Q2 2026, indicating underlying strength. Management cut 2026 guidance three times, with organic growth lowered to 5-6% and EPS guidance trimmed to $3.28-$3.32, amplifying investor pessimism.
BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade)
Boston Scientific is upgraded to 'Strong Buy' as market overreaction creates an attractive entry point for long-term investors. BSX trades at a forward P/E of 13.1, well below its historical average, despite robust profitability and solid Q2 2026 results. Growth headwinds from WATCHMAN and electrophysiology are offset by strong Interventional Cardiology and Vascular Therapies momentum.
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth
BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.
Boston Scientific: $43 Finally Prices In A Bad 2026
Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns.
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Boston Scientific (BSX) reached $43.1 at the closing of the latest trading day, reflecting a -4.14% change compared to its last close.
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
